Compare PERI & LXEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PERI | LXEO |
|---|---|---|
| Founded | 1999 | 2017 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | |
| Sector | Technology | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 412.5M | 418.9M |
| IPO Year | 2005 | 2023 |
| Metric | PERI | LXEO |
|---|---|---|
| Price | $9.82 | $5.74 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 9 |
| Target Price | $14.50 | ★ $18.44 |
| AVG Volume (30 Days) | 432.7K | ★ 855.6K |
| Earning Date | 05-12-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 39.81 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $654,000.00 |
| Revenue This Year | $9.95 | N/A |
| Revenue Next Year | $1.07 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $7.00 | $1.45 |
| 52 Week High | $11.44 | $10.99 |
| Indicator | PERI | LXEO |
|---|---|---|
| Relative Strength Index (RSI) | 61.03 | 40.72 |
| Support Level | $9.14 | $4.93 |
| Resistance Level | $10.25 | $6.08 |
| Average True Range (ATR) | 0.41 | 0.43 |
| MACD | 0.05 | 0.01 |
| Stochastic Oscillator | 65.99 | 37.77 |
Perion Network Ltd is a technology company. It offers online advertising and search solutions to brands, agencies, and publishers through desktop, mobile, and social channels. It connects advertisers to consumers across digital advertising channels, including search advertising, social, display, video, digital audio, digital out of home (DOOH), and Connected TV (CTV) advertising. The company earns prime revenue from search advertising and display advertising services. It operates in the business segment of High Impact Advertising solutions. Geographically, the company generates a majority of its revenue from the United States and the rest from other regions.
Lexeo Therapeutics Inc is a clinical-stage genetic medicines company committed to transforming healthcare by applying pioneering science to fundamentally alter how diseases are treated. The company focuses on preclinical and clinical stage gene therapies, specifically hereditary and acquired diseases with high unmet needs, which represent its sole business segment.